USP, government labs to launch drug quality network; GSK adds solar panels in RTP;

> The United States Pharmacopeial Convention and six government drug control labs in the Middle East and Northern Africa have joined to launch a drug quality improvement network. Article

> GlaxoSmithKline is preparing to install more solar panels at its Research Triangle Park campus. Item

> One-third of those polled say they are not sure if their company's CAPA system is robust enough to withstand a regulatory inspection. Release

> Officials in China believe they may have found the facility used to make counterfeits of Roche's Avastin. Article

> Cangene answers questions about its conversion to an electronic system for managing the training of plant workers. Interview

> Capillary electrophoresis machines are ready for installation in Cambodia and Congo, part of a European initiative to use the low-cost, easy to operate gear to analyze commonly counterfeited medicines. Article

> Material costs for plastic bottles and blister packs have risen by double-digit percentages over the past two years. Release

> Officials have approved a plan for connecting a Merck facility with the local water treatment plant to accommodate 300,000 gallons per day, about one-third of the West Point, PA, plant's wastewater. News

> Canada's Paralympic gold medal-winning curling team captain has pleaded guilty in the U.S. to selling counterfeit erectile-dysfunction drugs. Article

> Albania is setting up a pharmacovigilance center to monitor undesirable drug effects and develop measures for their prevention. Story

> Microscan has unveiled VS-1 Track and Trace, a solution for inspecting and verifying package label content. Microscan release

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.